Costimulatory pathways in transplantation

[1]  M. Sayegh,et al.  T-cell co-stimulatory blockade in kidney transplantation: back to the bench , 2011, Kidney international supplements.

[2]  F. Preffer,et al.  Mechanisms of Donor‐Specific Tolerance in Recipients of Haploidentical Combined Bone Marrow/Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  S. Beyaz,et al.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. , 2011, Blood.

[4]  K. Lamb,et al.  Long‐Term Renal Allograft Survival in the United States: A Critical Reappraisal , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  A. Mehta,et al.  Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  W. Marks,et al.  Immunosuppression with Belatacept‐Based, Corticosteroid‐Avoiding Regimens in De Novo Kidney Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  G. Blancho,et al.  A more selective costimulatory blockade of the CD28‐B7 pathway , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  T. Wekerle,et al.  Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism , 2010, Current opinion in organ transplantation.

[9]  A. Kirk,et al.  LFA-1-specific therapy prolongs allograft survival in rhesus macaques. , 2010, The Journal of clinical investigation.

[10]  Ansuman T. Satpathy,et al.  Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression , 2010, The Journal of experimental medicine.

[11]  R. Wiseman,et al.  An MHC‐Defined Primate Model Reveals Significant Rejection of Bone Marrow After Mixed Chimerism Induction Despite Full MHC Matching , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  T. Wekerle,et al.  Transplantation tolerance through mixed chimerism , 2010, Nature Reviews Nephrology.

[13]  P. Friend,et al.  Five-year safety and efficacy of belatacept in renal transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[14]  H. François,et al.  Co-signals in organ transplantation , 2010, Current opinion in organ transplantation.

[15]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[16]  F. Wrba,et al.  Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoreductive Conditioning , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  K. Murphy,et al.  Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. , 2010, Annual review of immunology.

[18]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  R. Pierson,et al.  Inducing CTLA-4–Dependent Immune Regulation by Selective CD28 Blockade Promotes Regulatory T Cells in Organ Transplantation , 2010, Science Translational Medicine.

[21]  J. Rodriguez-Barbosa,et al.  Hvem/light/btla/cd160 Cosignaling Pathways as Targets for Immune Regulation , 2009 .

[22]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[23]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[24]  T. Hünig,et al.  Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. , 2009, Blood.

[25]  G. Bishop,et al.  CD40 and autoimmunity: the dark side of a great activator. , 2009, Seminars in immunology.

[26]  Z. Milas,et al.  Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation , 2009, The Journal of Immunology.

[27]  A. Sharpe,et al.  SnapShot: B7/CD28 Costimulation , 2009, Cell.

[28]  X. Li,et al.  Costimulatory pathways in transplantation: challenges and new developments , 2009, Immunological reviews.

[29]  C. Larsen,et al.  Translating costimulation blockade to the clinic: lessons learned from three pathways , 2009, Immunological reviews.

[30]  G. Freeman,et al.  The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation , 2009, Immunological reviews.

[31]  V. Kuchroo,et al.  The costimulatory role of TIM molecules , 2009, Immunological reviews.

[32]  M. Sykes,et al.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. , 2009, Blood.

[33]  Manuel Rubio,et al.  CD28 Co-Stimulation Down Regulates Th17 Development , 2009, PloS one.

[34]  R. Gold,et al.  Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice , 2009, PLoS ONE.

[35]  M. Colombo,et al.  CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. , 2008, Immunity.

[36]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[37]  G. Freeman,et al.  Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. , 2008, Blood.

[38]  J. Wain,et al.  Comparison of lung and kidney allografts in induction of tolerance by a mixed-chimerism approach in cynomolgus monkeys. , 2008, Transplantation proceedings.

[39]  T. Niki,et al.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.

[40]  G. Freeman,et al.  CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator , 2008, Nature Immunology.

[41]  L. Turka,et al.  The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. , 2008, The Journal of clinical investigation.

[42]  V. Kuchroo,et al.  Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. , 2008, The Journal of clinical investigation.

[43]  E. Engleman,et al.  Tolerance and chimerism after renal and hematopoietic-cell transplantation. , 2008, The New England journal of medicine.

[44]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[45]  G. Freeman,et al.  TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. , 2007, Immunity.

[46]  K. Murphy,et al.  Combined Coinhibitory and Costimulatory Modulation with Anti‐BTLA and CTLA4Ig Facilitates Tolerance in Murine Islet Allografts , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  K. Murphy,et al.  Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. , 2007, Transplantation.

[48]  S. Nakae,et al.  TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. , 2007, Blood.

[49]  Wenda Gao,et al.  OX40 costimulation turns off Foxp3+ Tregs. , 2007, Blood.

[50]  T. So,et al.  Cutting Edge: OX40 Inhibits TGF-β- and Antigen-Driven Conversion of Naive CD4 T Cells into CD25+Foxp3+ T cells1 , 2007, The Journal of Immunology.

[51]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[52]  M. Pescovitz,et al.  A Phase I/II Randomized Open‐Label Multicenter Trial of Efalizumab, a Humanized Anti‐CD11a, Anti‐LFA‐1 in Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  J. Casasnovas,et al.  Structures of T Cell Immunoglobulin Mucin Receptors 1 and 2 Reveal Mechanisms for Regulation of Immune Responses by the TIM Receptor Family , 2007, Immunity.

[54]  Sambasiva P Rao,et al.  Epitope-Dependent Effect of Anti-Murine TIM-1 Monoclonal Antibodies on T Cell Activity and Lung Immune Responses , 2007, The Journal of Immunology.

[55]  M. Rigby,et al.  Induction of Chimerism in Rhesus Macaques through Stem Cell Transplant and Costimulation Blockade‐Based Immunosuppression , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[56]  R. Storb,et al.  CD154 Blockade and Donor-Specific Transfusions in DLA-Identical Marrow Transplantation in Dogs Conditioned with 1-Gy Total Body Irradiation , 2007, Biology of Blood and Marrow Transplantation.

[57]  G. Freeman,et al.  Immunoglobulin A (IgA) Is a Natural Ligand of Hepatitis A Virus Cellular Receptor 1 (HAVCR1), and the Association of IgA with HAVCR1 Enhances Virus-Receptor Interactions , 2007, Journal of Virology.

[58]  H. Tajiri,et al.  Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease1 , 2006, The Journal of Immunology.

[59]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[60]  R. Colvin,et al.  Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  David C. Gondek,et al.  Mast cells are essential intermediaries in regulatory T-cell tolerance , 2006, Nature.

[62]  M. Gilliet,et al.  OX40 ligand shuts down IL-10-producing regulatory T cells , 2006, Proceedings of the National Academy of Sciences.

[63]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[64]  C. Cilio,et al.  Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppression , 2006, Immunology.

[65]  E. Silbergeld,et al.  Cutting Edge: T Cell Ig Mucin-3 Reduces Inflammatory Heart Disease by Increasing CTLA-4 during Innate Immunity1 , 2006, The Journal of Immunology.

[66]  A. Kirk,et al.  A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  C. Larsen,et al.  Transplant Tolerance in Non‐Human Primates: Progress, Current Challenges and Unmet Needs , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  G. Freeman,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[69]  J. Bluestone,et al.  CTLA4Ig: bridging the basic immunology with clinical application. , 2006, Immunity.

[70]  T. Wekerle,et al.  New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig , 2006 .

[71]  R. Ahmed,et al.  Patients, Pathogens, and Protective Immunity: The Relevance of Virus-Induced Alloreactivity in Transplantation , 2006, The Journal of Immunology.

[72]  M. Tsai,et al.  Mast Cells Enhance T Cell Activation: Importance of Mast Cell Costimulatory Molecules and Secreted TNF1 , 2006, The Journal of Immunology.

[73]  R. Gill,et al.  LFA‐1 (CD11a) as a Therapeutic Target , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[74]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[75]  V. Dharnidharka.  Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[76]  K. Murphy,et al.  Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts1 , 2005, The Journal of Immunology.

[77]  C. Usal,et al.  Anti‐CD28 Antibody‐Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR− Class II− B7+ Regulatory Cells , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[78]  T. Fehr,et al.  Early regulation of CD8 T cell alloreactivity by CD4+CD25– T cells in recipients of anti‐CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor‐reactive CD8+ T cells, precluding a role for sustained regulation , 2005, European journal of immunology.

[79]  R. Gold,et al.  Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis , 2005, The Journal of experimental medicine.

[80]  T. Strom,et al.  Roles of Deletion and Regulation in Creating Mixed Chimerism and Allograft Tolerance Using a Nonlymphoablative Irradiation-Free Protocol , 2005, The Journal of Immunology.

[81]  H. Bergmeister,et al.  The Role of Non‐Deletional Tolerance Mechanisms in a Murine Model of Mixed Chimerism with Costimulation Blockade , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[82]  G. Remuzzi,et al.  Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells , 2005, Transplantation.

[83]  M. Colombo,et al.  Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.

[84]  G. Berry,et al.  TIM-1 induces T cell activation and inhibits the development of peripheral tolerance , 2005, Nature Immunology.

[85]  V. Kuchroo,et al.  TIM-4 is the ligand for TIM-1, and the TIM-1–TIM-4 interaction regulates T cell proliferation , 2005, Nature Immunology.

[86]  P. Linsley,et al.  Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[87]  R. Gill,et al.  Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. , 2005, Diabetes.

[88]  N. Kenyon,et al.  Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival1 , 2005, The Journal of Immunology.

[89]  P. Lake,et al.  Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection , 2004, The Journal of Immunology.

[90]  A. Sharpe,et al.  4-1BB and OX40 Act Independently to Facilitate Robust CD8 and CD4 Recall Responses1 , 2004, The Journal of Immunology.

[91]  M. Sykes,et al.  Tolerance in mixed chimerism - a role for regulatory cells? , 2004, Trends in immunology.

[92]  R. Colvin,et al.  CD154 Blockade for Induction of Mixed Chimerism and Prolonged Renal Allograft Survival in Nonhuman Primates , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[93]  K. Okumura,et al.  Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[94]  T. Berney,et al.  Anti‐CD154 mAb Treatment But Not Recipient CD154 Deficiency Leads to Long‐Term Survival of Xenogeneic Islet Grafts , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[95]  I. Ishikawa,et al.  Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells1 , 2004, The Journal of Immunology.

[96]  M. Sykes,et al.  Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. , 2004, Blood.

[97]  K. Sugamura,et al.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 , 2004, Nature Reviews Immunology.

[98]  J. Yates,et al.  Differential expression of CTLA‐4 among T cell subsets , 2004, Clinical and experimental immunology.

[99]  C. Baecher-Allan,et al.  T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis1 , 2004, The Journal of Immunology.

[100]  D. Boumpas,et al.  Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients , 2004, Lupus.

[101]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[102]  C. Riccardi,et al.  Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.

[103]  D. Sachs,et al.  Mixed chimerism and transplantation tolerance. , 2004, Transplantation.

[104]  T. Strom,et al.  Critical Role of OX40 in CD28 and CD154-Independent Rejection1 , 2004, The Journal of Immunology.

[105]  R. Stern.  A promising step forward in psoriasis therapy. , 2003, Journal of the American Medical Association (JAMA).

[106]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[107]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[108]  Y. Shimizu.  LFA-1: more than just T cell Velcro , 2003, Nature Immunology.

[109]  V. Kuchroo,et al.  Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance , 2003, Nature Immunology.

[110]  G. Freeman,et al.  Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance , 2003, Nature Immunology.

[111]  E. Simpson,et al.  Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade , 2003, Nature Medicine.

[112]  H. Waldmann.  The new immunosuppression: just kill the T cell , 2003, Nature Medicine.

[113]  G. Freeman,et al.  Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.

[114]  Wenda Gao,et al.  Stimulating PD-1–negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival1 , 2003, Transplantation.

[115]  G. Freeman,et al.  The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. , 2003, The Journal of clinical investigation.

[116]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[117]  R. Morris,et al.  Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys1 , 2003, Transplantation.

[118]  G. Freeman,et al.  The TIM gene family: emerging roles in immunity and disease , 2003, Nature Reviews Immunology.

[119]  T. Wekerle,et al.  Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral tolerance , 2003, Transplantation.

[120]  J. Hart,et al.  Role of 4‐1BB in Allograft Rejection Mediated by CD8+ T Cells , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[121]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[122]  M. Sayegh,et al.  The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo 1 , 2003, The Journal of Immunology.

[123]  T. Hünig,et al.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist , 2003, European journal of immunology.

[124]  D. Harlan,et al.  Studies Investigating Pretransplant Donor-Specific Blood Transfusion, Rapamycin, and the CD154-Specific Antibody IDEC-131 in a Nonhuman Primate Model of Skin Allotransplantation1 , 2003, The Journal of Immunology.

[125]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[126]  J. Gutiérrez-Ramos,et al.  Programmed Death-1 Targeting Can Promote Allograft Survival1 , 2002, The Journal of Immunology.

[127]  T. Okazaki,et al.  New regulatory co-receptors: inducible co-stimulator and PD-1. , 2002, Current opinion in immunology.

[128]  F. Vincenti.  What's in the Pipeline? New Immunosuppressive Drugs in Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[129]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[130]  D. Harlan,et al.  Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. , 2002, Transplantation.

[131]  M. Sykes,et al.  Mechanisms of transplant tolerance induction using costimulatory blockade. , 2002, Current opinion in immunology.

[132]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[133]  J. Bluestone,et al.  Cutting Edge: Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells1 , 2002, The Journal of Immunology.

[134]  A. Valujskikh,et al.  Primed Allospecific T Cells Prevent the Effects of Costimulatory Blockade on Prolonged Cardiac Allograft Survival in Mice , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[135]  P. Walicke,et al.  Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. , 2002, Transplant immunology.

[136]  S. Busfield,et al.  Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft Survival , 2002, The Journal of experimental medicine.

[137]  G. Freeman,et al.  PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.

[138]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.

[139]  L. Tesson,et al.  Prolonged Blockade of CD40-CD40 Ligand Interactions by Gene Transfer of CD40Ig Results in Long-Term Heart Allograft Survival and Donor-Specific Hyporesponsiveness, But Does Not Prevent Chronic Rejection1 , 2002, The Journal of Immunology.

[140]  M. Croft,et al.  4–1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity , 2002, European journal of immunology.

[141]  M. Taal,et al.  Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. , 2002, Journal of the American Society of Nephrology : JASN.

[142]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[143]  C. Larsen,et al.  The Role of TNF Receptor and TNF Superfamily Molecules in Organ Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[144]  E. Clark,et al.  Tumor Necrosis Factor-α Regulates the Expression of Inducible Costimulator Receptor Ligand on CD34+ Progenitor Cells during Differentiation into Antigen Presenting Cells* , 2001, The Journal of Biological Chemistry.

[145]  M. Sykes,et al.  Mechanisms Involved in the Establishment of Tolerance Through Costimulatory Blockade and BMT: Lack of Requirement for CD40L‐Mediated Signaling for Tolerance or Deletion of Donor‐reactive CD4+ Cells , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[146]  H. Gudmundsdottir,et al.  A Closer Look at Homeostatic Proliferation of CD4+ T Cells: Costimulatory Requirements and Role in Memory Formation1 , 2001, The Journal of Immunology.

[147]  P. Rogers,et al.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. , 2001, Immunity.

[148]  D. Harlan,et al.  INDUCTION THERAPY WITH MONOCLONAL ANTIBODIES SPECIFIC FOR CD80 AND CD86 DELAYS THE ONSET OF ACUTE RENAL ALLOGRAFT REJECTION IN NON-HUMAN PRIMATES1 , 2001, Transplantation.

[149]  M. Debenedette,et al.  4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy1 , 2001, The Journal of Immunology.

[150]  J. Gutiérrez-Ramos,et al.  Importance of ICOS–B7RP-1 costimulation in acute and chronic allograft rejection , 2001, Nature Immunology.

[151]  L. Turka,et al.  Peripheral Deletion After Bone Marrow Transplantation with Costimulatory Blockade Has Features of Both Activation-Induced Cell Death and Passive Cell Death1 , 2001, The Journal of Immunology.

[152]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[153]  J. Allison,et al.  ICOS co-stimulatory receptor is essential for T-cell activation and function , 2001, Nature.

[154]  T. Pawson,et al.  ICOS is essential for effective T-helper-cell responses , 2001, Nature.

[155]  C. Larsen,et al.  Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts1 , 2000, The Journal of Immunology.

[156]  P. Libby,et al.  Host CD40 Ligand Deficiency Induces Long-Term Allograft Survival and Donor-Specific Tolerance in Mouse Cardiac Transplantation But Does Not Prevent Graft Arteriosclerosis1 , 2000, The Journal of Immunology.

[157]  A. Oxenius,et al.  Inducible Costimulator Protein (Icos) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection , 2000, The Journal of experimental medicine.

[158]  C. Larsen,et al.  Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoreductive Conditioning1 , 2000, The Journal of Immunology.

[159]  S. Lehar,et al.  The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. , 2000, Immunity.

[160]  L. Presta,et al.  EFFECTS OF HUMANIZED MONOCLONAL ANTIBODY TO RHESUS CD11a IN RHESUS MONKEY CARDIAC ALLOGRAFT RECIPIENTS12 , 2000 .

[161]  M. Sykes,et al.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment , 2000, Nature Medicine.

[162]  M. Nicolls,et al.  Anti-LFA-1 Therapy Induces Long-Term Islet Allograft Acceptance in the Absence of IFN-γ or IL-41 , 2000, The Journal of Immunology.

[163]  D. Harlan,et al.  Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis , 2000, The Journal of experimental medicine.

[164]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[165]  P. Lane.  Role of Ox40 Signals in Coordinating Cd4 T Cell Selection, Migration, and Cytokine Differentiation in T Helper (Th)1 and Th2 Cells , 2000, The Journal of experimental medicine.

[166]  C. Larsen,et al.  Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. , 1999, The Journal of clinical investigation.

[167]  M. Bachmann,et al.  Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. , 1999, Journal of immunology.

[168]  P. Lane,et al.  Compromised Ox40 Function in Cd28-Deficient Mice Is Linked with Failure to Develop Cxc Chemokine Receptor 5–Positive Cd4 Cells and Germinal Centers , 1999, The Journal of experimental medicine.

[169]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. , 1999, Blood.

[170]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[171]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[172]  D. Harlan,et al.  Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. , 1999, Diabetes.

[173]  D. Harlan,et al.  Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates , 1999, Nature Medicine.

[174]  A. Sharpe,et al.  B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) , 1999, The Journal of experimental medicine.

[175]  M. Croft,et al.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. , 1998, Journal of immunology.

[176]  B. Kwon,et al.  Role of 4-1BB in immune responses. , 1998, Seminars in immunology.

[177]  J. Borst,et al.  Tumor necrosis factor receptor family members in the immune system. , 1998, Seminars in immunology.

[178]  Yuan Zhang,et al.  The Human Homolog of HAVcr-1 Codes for a Hepatitis A Virus Cellular Receptor , 1998, Journal of Virology.

[179]  L. Turka,et al.  The role of T-cell costimulatory activation pathways in transplant rejection. , 1998, The New England journal of medicine.

[180]  M. Sykes,et al.  Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance , 1998, The Journal of experimental medicine.

[181]  K. Nadeau,et al.  Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. , 1998, The Journal of clinical investigation.

[182]  Joseph V. Bonventre,et al.  Kidney Injury Molecule-1 (KIM-1), a Putative Epithelial Cell Adhesion Molecule Containing a Novel Immunoglobulin Domain, Is Up-regulated in Renal Cells after Injury* , 1998, The Journal of Biological Chemistry.

[183]  L. Turka,et al.  Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. , 1997, Transplantation.

[184]  G. Szot,et al.  Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. , 1997, Journal of immunology.

[185]  C. Larsen,et al.  The CD40 pathway in allograft rejection, acceptance, and tolerance. , 1997, Current opinion in immunology.

[186]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[187]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[188]  G. Szot,et al.  Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning , 1997, Nature Medicine.

[189]  J. Banchereau,et al.  Functions of CD40 on B cells, dendritic cells and other cells. , 1997, Current opinion in immunology.

[190]  P. Nickerson,et al.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. , 1997, Journal of immunology.

[191]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[192]  D. Durand,et al.  A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. , 1996, Transplantation.

[193]  M. Jackson,et al.  Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[194]  K. Nadeau,et al.  Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[195]  M. Isobe,et al.  Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. , 1996, Transplantation.

[196]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[197]  L. Spain,et al.  The in vivo mechanism of action of CTLA4Ig. , 1996, Journal of immunology.

[198]  W. Strober,et al.  The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response , 1996, The Journal of experimental medicine.

[199]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[200]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[201]  G. Gray,et al.  Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. , 1995, Blood.

[202]  R. Colvin,et al.  Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys , 1995, Transplantation.

[203]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[204]  P. Linsley,et al.  CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. , 1994, Transplantation.

[205]  D. Campana,et al.  Hyper IgM syndrome associated with defective CD40-mediated B cell activation. , 1994, The Journal of clinical investigation.

[206]  M. Sykes,et al.  Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. , 1994, Journal of immunology.

[207]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[208]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[209]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[210]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[211]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[212]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[213]  M. Isobe,et al.  Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. , 1992, Science.

[214]  T. Owens.  A role for adhesion molecules in contact‐dependent T help for B cells , 1991, European journal of immunology.

[215]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[216]  K. Horgan,et al.  The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. , 1990, Journal of immunology.

[217]  D. Olive,et al.  Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults. , 1989, Bone marrow transplantation.

[218]  D. Sachs,et al.  Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen , 1989, The Journal of experimental medicine.

[219]  T. Springer,et al.  Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. , 1988, Journal of immunology.

[220]  A. Singer,et al.  Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection , 1987, The Journal of experimental medicine.

[221]  R. Schwartz,et al.  Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo , 1987, The Journal of experimental medicine.

[222]  D. Sachs,et al.  Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts , 1984, Nature.

[223]  K. Lafferty,et al.  A new analysis of allogeneic interactions. , 1975, The Australian journal of experimental biology and medical science.

[224]  Shimon Sakaguchi,et al.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.

[225]  D. Mueller.  Mechanisms maintaining peripheral tolerance , 2010, Nature Immunology.

[226]  T. Hünig.  Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. , 2007, Advances in immunology.

[227]  M. Gilliet,et al.  OX 40 ligand shuts down IL-10-producing regulatory T cells , 2006 .

[228]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[229]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[230]  A. Sharpe,et al.  4-1 BB and OX 40 Act Independently to Facilitate Robust CD 8 and CD 4 Recall Responses 1 , 2004 .

[231]  J. Markmann,et al.  Homeostatic proliferation is a barrier to transplantation tolerance , 2004, Nature Medicine.

[232]  小菅 寿徳.  Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway , 2004 .

[233]  J. Gutiérrez-Ramos,et al.  Programmed Death-1 Targeting Can Promote Allograft Survival , 2002 .

[234]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[235]  E. Clark,et al.  Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells. , 2001, The Journal of biological chemistry.

[236]  Andreas Hutloff,et al.  ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 , 1999, Nature.